Aim: To ascertain whether resveratrol affects the expression of free fatty acids (FFA)-induced profibrogenic genes, death receptors, and/or apoptosis-related molecules in human hepatic stellate cells, using the LX-2 cell line.

Methods: Cells were cultured in the presence of FFAs (2:1 oleate : palmitate) and subsequently treated with resveratrol. Gene expression rates were determined by quantitative real-time PCR. The 50% lethal dose (LD(50)) of resveratrol in the presence of FFAs was assessed with the MTT viability test.

Results: Compared to vehicle controls, incubation of LX-2 cells with 0.5 mM FFAs induced profibrogenic genes (alpha-SMA x 2.9; TGF-beta1 x 1.6; TIMP-1 x 1.4), death receptors (CD95/Fas x 3.8; TNFR-1 x 1.4), and anti-apoptotic molecules (Bcl-2 x 2.3; Mcl-1 x 1.3). Subsequent addition of 15 microM resveratrol (LD(50) = 23.2 microM) significantly (P < 0.05) upregulated further these genes (alpha-SMA x 6.5; TGF-beta1 x 1.9; TIMP-1 x 2.2; CD95/Fas x 13.1, TNFR-1 x 2.1; Bcl-2 x 3.6; Mcl-1 x 1.9). Importantly, this effect was only observed in the presence of FFAs.

Conclusion: Resveratrol amplifies the profibrogenic activation of human hepatic LX-2 stellate cells. This finding raises the possibility that in obese patients with elevated FFAs reserveratrol could provoke hepatic fibrogenesis. In-vivo studies are necessary to further validate this conclusion.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2893585PMC
http://dx.doi.org/10.1111/j.1872-034X.2008.00485.xDOI Listing

Publication Analysis

Top Keywords

human hepatic
12
stellate cells
12
resveratrol amplifies
8
amplifies profibrogenic
8
free fatty
8
fatty acids
8
hepatic stellate
8
profibrogenic genes
8
death receptors
8
presence ffas
8

Similar Publications

Backgrounds And Aims: CD8+T cells are crucially associated with the fight against hepatitis B virus (HBV) infection. CD161 has been shown to express remarkably on HCV-specific CD8+T cells. However, the accurate function of CD161+CD8+T cells in HBV immunity or pathogenesis remains undetermined.

View Article and Find Full Text PDF

Human liver cell-based assays for the prediction of hepatic bile acid efflux transporter inhibition by drugs.

Expert Opin Drug Metab Toxicol

January 2025

Institut de R&D Servier, Paris-Saclay, F-91190 Gif-sur-Yvette, France.

Introduction: Drug-mediated inhibition of bile salt efflux transporters may cause liver injury. In vitro prediction of drug effects toward canalicular and/or sinusoidal efflux of bile salts from human hepatocytes is therefore a major issue, which can be addressed using liver cell-based assays.

Area Covered: This review, based on a thorough literature search in the scientific databases PubMed and Web of Science, provides key information about hepatic transporters implicated in bile salt efflux, the human liver cell models available for investigating functional inhibition of bile salt efflux, the different methodologies used for this purpose, and the modes of expression of the results.

View Article and Find Full Text PDF

The kinetically-derived maximal dose (KMD) is defined as the maximum external dose at which kinetics are unchanged relative to lower doses, e.g., doses at which kinetic processes are not saturated.

View Article and Find Full Text PDF

Evaluation of the anti-cholelithiasis activity of vinegar-soaked Ficus carica fruit in adults: A randomized controlled trial.

Pak J Pharm Sci

January 2025

Department of Pathobiology and Biomedical Sciences, Muhammad Nawaz Sharif University of Agriculture, Multan, Pakistan/Ali-Ul-Murtaza Department of Rehabilitation Sciences, Muhammad Institute of Medical and Allied Sciences, Multan, Pakistan.

This study aimed to evaluate the efficacy of vinegar-soaked Ficus carica fruits (VSFCF) for managing cholelithiasis in adults. A parallel-group, single-blinded, randomized controlled trial at Noreen Nishat Welfare Hospital, Khanewal, Pakistan, was conducted from December 2023 to February 2024. Fifty adults with ultrasound-confirmed cholelithiasis were randomly assigned to receive either VSFCF (1 g/kg/day) or ursodiol (600 mg/day).

View Article and Find Full Text PDF

[Research progress on the role of efferocytosis in liver diseases].

Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi

January 2025

Central Laboratory, Chengdu University of TCM, School of Clinical Medicine, Chengdu University of TCM, Chengdu 610072, China.

Efferocytosis refers to the process of phagocytes engulfing and clearing the cells after programmed cell death. In recent years, an increasing number of studies have shown that the mechanisms of efferocytosis are closely related to drug-induced liver injury, hepatic ischemia-reperfusion injury, viral hepatitis, cholestatic liver diseases, metabolic-associated fatty liver disease, alcoholic liver disease, and other liver disorders. This review summarized the research progress on the role of efferocytosis in liver diseases, with the hope of providing new targets for the prevention and treatment of liver diseases.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!